Clinical Trial Detail

NCT ID NCT01164163
Title INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Children's Oncology Group|National Cancer Institute (NCI)
Indications

myelodysplastic/myeloproliferative neoplasm

childhood leukemia

Advanced Solid Tumor

Therapies

Ruxolitinib

Age Groups: child

Additional content available in CKB BOOST